Mass General Team's INSTALL Platform Solves Gene Therapy's Immune Toxicity Problem, Enabling Safe Non-Viral DNA Insertion in Living Mice
A Nature paper describes INSTALL, a gene editing platform using circular single-stranded DNA to insert therapeutic genes without triggering fatal immune responses, keeping mice healthy at doses where conventional DNA proved lethal.
Gene therapies that permanently correct inherited diseases require inserting large stretches of DNA into a patient’s genome. The dominant approach uses viral vectors — engineered viruses that carry therapeutic genes into cells — but viral delivery is expensive to manufacture, difficult to redose, and limited in the size of genetic cargo it can carry. The alternative, delivering naked double-stranded DNA (dsDNA) via lipid nanoparticles, has been stymied by a biological barrier: mammalian cells treat foreign dsDNA as a danger signal, triggering inflammatory cascades through the cGAS-STING pathway that can be fatal at therapeutic doses.
A team led by Benjamin Kleinstiver and Connor Tou at Massachusetts General Hospital has now demonstrated a way around that barrier. Their platform, described in a Nature paper published March 11, replaces conventional dsDNA donors with engineered circular single-stranded DNA molecules that evade the innate immune sensors responsible for toxicity. The technique, called INSTALL — integration through nucleus-synthesized template addition of large lengths — pairs these stealth DNA circles with recombinase enzymes that catalyze precise insertion of kilobase-scale genetic payloads at defined genomic locations.
How INSTALL works
The approach draws on a mechanism found in nature: many bacteriophages use circular single-stranded DNA genomes and recombinases to integrate their genetic material into bacterial chromosomes. The Kleinstiver lab adapted this strategy for mammalian cells by engineering circular single-stranded DNA molecules with a short double-stranded region that reconstitutes the recognition sequence required by recombinase enzymes. The largely single-stranded architecture keeps the molecule below the detection threshold of cGAS, which according to the researchers demonstrates more than tenfold weaker affinity for single-stranded DNA than for double-stranded DNA.
The most advanced variant, called INSTALL-2e, pre-anneals the circular single-stranded DNA to short chemically modified oligonucleotides. This reconstitutes just enough double-stranded structure for recombinase function while keeping the overall molecule invisible to innate immune sensors.
Mouse experiments reveal a stark safety divide
The contrast between INSTALL and conventional dsDNA delivery in mice was dramatic. When delivered via lipid nanoparticles at equivalent doses, double-stranded DNA killed all treated mice within one to three days. Mice treated with INSTALL-2e at the same or higher doses showed no observable adverse effects and were, according to the paper, “nearly indistinguishable from PBS-treated or mRNA-treated controls in terms of viability and behavior.”
A two-dose protocol achieved approximately one percent bulk liver integration, with genome-wide sequencing confirming on-target specificity and minimal off-target insertion. While one percent may sound modest, the researchers note that even low-level integration can be therapeutically meaningful for liver-expressed proteins, drawing a parallel to the trajectory of siRNA and mRNA therapeutics, where years of chemical optimization transformed initially marginal efficiencies into viable drug classes.
Proof-of-concept in human cells
In human T cells, INSTALL achieved approximately four times higher integration efficiency compared with dsDNA donors. The system successfully accommodated cargo genes exceeding six kilobases, including a 4.8-kilobase copy of the ABCD1 gene responsible for X-linked adrenoleukodystrophy (ALD). The inserted gene produced functional protein, establishing therapeutic proof-of-concept for at least one monogenic disease.
The platform proved compatible with multiple classes of recombinases — both protein-guided and RNA-guided — suggesting broad applicability across different integration strategies.
A mutation-agnostic approach
One of the most significant implications of INSTALL is its potential to simplify treatment development for inherited diseases. Rather than designing a unique correction for each of the hundreds or thousands of distinct mutations that can cause a given genetic disorder, INSTALL enables a “mutation-agnostic” strategy: inserting a complete, functional copy of the relevant gene regardless of the specific mutation a patient carries.
Full Circles Therapeutics, the Cambridge-based company that manufactures the circular single-stranded DNA used in the study through its proprietary C4DNA platform, highlighted cystic fibrosis and beta-thalassemia as potential therapeutic targets. Howard Wu, the company’s co-founder and CEO, described circular single-stranded DNA as “a fundamentally different genetic payload” compared with conventional approaches.
Limitations and the road ahead
The researchers acknowledged that the current one percent in vivo integration efficiency remains insufficient for most therapeutic applications. They identified three priority areas for improvement: optimizing lipid nanoparticle co-delivery of recombinase mRNA and circular single-stranded DNA donors, refining chemical modifications for enhanced stability, and engineering recombinases for direct integration at therapeutic loci without requiring pre-installed landing sites.
The work arrives at a moment when the gene therapy field is actively seeking alternatives to viral vectors. The FDA’s recent framework for accelerating individualized therapies for ultra-rare diseases, announced in February 2026, has increased pressure to develop scalable, non-viral delivery systems that can be manufactured quickly and affordably. If INSTALL’s efficiency can be improved through the kind of iterative chemical optimization that transformed mRNA therapeutics from a laboratory curiosity into a global vaccine platform, the technique could open a path toward non-viral gene therapies for a broad range of inherited diseases.